As brigatinib was approved as a first-line therapy for NSCLC only recently (May 2020), the present study focuses on brigatinib use in the later-line treatment settings.10 Most of the patients in this study received ALK-TKIs (over 80%) prior to initiating brigatinib therapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.